Jennifer Corny1, Denis Lebel1, Benoit Bailey2, Jean-François Bussières3. 1. Pharmacy Practice Research Unit, Pharmacy Department, CHU Sainte-Justine, Montréal, Québec, Canada; 2. Division of Emergency Medicine, Department of Pediatrics, CHU Sainte-Justine, Montréal, Québec, Canada; 3. Pharmacy Practice Research Unit, Pharmacy Department, CHU Sainte-Justine, Montréal, Québec, Canada; ; Faculty of Pharmacy, Université de Montréal, Montréal.
Abstract
OBJECTIVES: Governmental agencies (US Food and Drug Administration and European Medicines Agency) implemented initiatives to improve pediatric clinical research, starting in 1997 and 2007, respectively. The aim of this review was to quantify the unlicensed and off-label drug uses in children before and after these implementations. METHODS: Literature review of unlicensed and off-label drug uses was performed on PubMed and Google-Scholar from 1985 to 2014. Relevant titles/abstracts were reviewed, and articles were included if evaluating unlicensed/off-label drug uses, with a clear description of health care setting and studied population. Included articles were divided into 3 groups: studies conducted in United States (before/after 2007), in Europe (before/after 2007), and in other countries. RESULTS: Of the 48 articles reviewed, 27 were included. Before implementation of pediatric initiatives, global unlicensed drug use rate in Europe was found to be 0.2% to 36% for inpatients and 0.3% to 16.6% for outpatients. After implementation, it marginally decreased to 11.4% and 1.26% to 6.7%, respectively. Concerning off-label drug use rates, it was found to be 18% to 66% for inpatients and 10.5% to 37.5% for outpatients before the implementation. After implementation, it decreased marginally to 33.2% to 46.5% and to 3.3% to 13.5%, respectively. In other countries, unlicensed and off-label drug use rates were found to be, respectively, 8% to 27.3% and 11% to 47%. CONCLUSIONS: Governmental initiatives to improve clinical research conducted in children seem to have had a marginal effect to decrease the unlicensed and off-label drug uses prevalence in Europe.
OBJECTIVES: Governmental agencies (US Food and Drug Administration and European Medicines Agency) implemented initiatives to improve pediatric clinical research, starting in 1997 and 2007, respectively. The aim of this review was to quantify the unlicensed and off-label drug uses in children before and after these implementations. METHODS: Literature review of unlicensed and off-label drug uses was performed on PubMed and Google-Scholar from 1985 to 2014. Relevant titles/abstracts were reviewed, and articles were included if evaluating unlicensed/off-label drug uses, with a clear description of health care setting and studied population. Included articles were divided into 3 groups: studies conducted in United States (before/after 2007), in Europe (before/after 2007), and in other countries. RESULTS: Of the 48 articles reviewed, 27 were included. Before implementation of pediatric initiatives, global unlicensed drug use rate in Europe was found to be 0.2% to 36% for inpatients and 0.3% to 16.6% for outpatients. After implementation, it marginally decreased to 11.4% and 1.26% to 6.7%, respectively. Concerning off-label drug use rates, it was found to be 18% to 66% for inpatients and 10.5% to 37.5% for outpatients before the implementation. After implementation, it decreased marginally to 33.2% to 46.5% and to 3.3% to 13.5%, respectively. In other countries, unlicensed and off-label drug use rates were found to be, respectively, 8% to 27.3% and 11% to 47%. CONCLUSIONS: Governmental initiatives to improve clinical research conducted in children seem to have had a marginal effect to decrease the unlicensed and off-label drug uses prevalence in Europe.
Authors: Ermindo R Di Paolo; Hans Stoetter; Jacques Cotting; Peter Frey; Mario Gehri; Maja Beck-Popovic; Jean-François Tolsa; Sergio Fanconi; André Pannatier Journal: Swiss Med Wkly Date: 2006-04-01 Impact factor: 2.193
Authors: Nicolino Ruperto; Irmgard Eichler; Ralf Herold; Gilles Vassal; Carlo Giaquinto; Lars Hjorth; Adolf Valls-i-Soler; Christina Peters; Peter J Helms; Agnès Saint Raymond Journal: Arch Dis Child Date: 2011-11-27 Impact factor: 3.791
Authors: A Dick; S Keady; F Mohamed; S Brayley; M Thomson; B W Lloyd; R Heuschkel; N A Afzal Journal: Aliment Pharmacol Ther Date: 2003-02-15 Impact factor: 8.171
Authors: Benedetta Guidi; Andrea Parziale; Luca Nocco; Aniello Maiese; Raffaele La Russa; Marco Di Paolo; Emanuela Turillazzi Journal: Int J Clin Pharm Date: 2021-09-08
Authors: Georgina Thompson; Charlotte I Barker; Laura Folgori; Julia A Bielicki; John S Bradley; Irja Lutsar; Mike Sharland Journal: BMJ Open Date: 2017-10-13 Impact factor: 2.692
Authors: Jenny W Sun; Sonia Hernández-Díaz; Sebastien Haneuse; Florence T Bourgeois; Seanna M Vine; Mark Olfson; Brian T Bateman; Krista F Huybrechts Journal: JAMA Psychiatry Date: 2021-01-01 Impact factor: 21.596